2/9
06:05 am
mnkd
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
Low
Report
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
2/6
03:46 am
mnkd
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
Medium
Report
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
1/29
01:59 pm
mnkd
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
1/26
10:43 am
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
1/26
10:31 am
mnkd
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
Low
Report
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
1/26
06:21 am
mnkd
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy [Yahoo! Finance]
Medium
Report
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy [Yahoo! Finance]
1/26
06:05 am
mnkd
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
Low
Report
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
1/23
12:56 pm
mnkd
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Medium
Report
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
1/22
04:00 am
mnkd
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative [Yahoo! Finance]
Medium
Report
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative [Yahoo! Finance]
1/19
08:12 am
mnkd
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers [Yahoo! Finance]
Medium
Report
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers [Yahoo! Finance]
1/14
08:21 pm
mnkd
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile [Yahoo! Finance]
Low
Report
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile [Yahoo! Finance]
1/14
07:36 am
mnkd
MannKind (NASDAQ:MNKD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
MannKind (NASDAQ:MNKD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/8
07:05 pm
mnkd
MannKind Provides Business Updates and 2026 Growth Drivers [Yahoo! Finance]
Low
Report
MannKind Provides Business Updates and 2026 Growth Drivers [Yahoo! Finance]
1/8
01:06 pm
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/8
08:05 am
mnkd
MannKind Provides Business Updates and 2026 Growth Drivers
Low
Report
MannKind Provides Business Updates and 2026 Growth Drivers
1/1
06:40 am
mnkd
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]
Low
Report
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]
12/30
06:47 am
mnkd
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years [Yahoo! Finance]
Low
Report
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years [Yahoo! Finance]
12/23
08:13 am
mnkd
MannKind Shares FUROSCIX® Business Updates [Yahoo! Finance]
Low
Report
MannKind Shares FUROSCIX® Business Updates [Yahoo! Finance]
12/23
08:05 am
mnkd
MannKind Shares FUROSCIX® Business Updates
Low
Report
MannKind Shares FUROSCIX® Business Updates
12/3
05:37 am
mnkd
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
Low
Report
Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]
12/1
08:05 am
mnkd
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
Low
Report
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
11/24
10:02 am
mnkd
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
Low
Report
MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/13
09:53 am
mnkd
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Medium
Report
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
11/11
04:32 pm
mnkd
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
MannKind to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]